STAGE III PANCREATIC CANCER AJCC V8

This early-stage trial tests two drugs together for people with pancreatic cancer that has spread. One drug starves cancer cells by removing a key nutrient, while the other blocks a growth signal. The goal is to find the safest dose and see if the combination can control the dise…

This early-phase trial tests a new drug (M6620) combined with a standard chemotherapy (irinotecan) in people with advanced solid tumors that have spread or can't be removed by surgery. The main goal is to find the safest dose and check for side effects. About 66 adults with cance…

This early-phase study tests a combination of two drugs (niraparib and dostarlimab) in 18 people with advanced breast, pancreas, or ovary cancers that have a BRCA gene mutation and have stopped responding to standard treatments. The goal is to see if the combo can shrink tumors b…

This early-phase trial tests a new drug combination for people with advanced pancreatic cancer that has a specific marker (mesothelin). The study combines a targeted chemotherapy (anetumab ravtansine) with immunotherapy drugs (nivolumab, ipilimumab) and standard chemo (gemcitabin…

This study tests a technique called sonoporation, which uses ultrasound and tiny bubbles to help chemotherapy drugs get into cancer cells more effectively. It includes 120 adults with advanced or hard-to-remove pancreatic cancer who are already scheduled for standard chemotherapy…

This early-stage trial was designed to test the safety of a new treatment called STIL101 for people with advanced pancreatic, colorectal, kidney, cervical cancer, or melanoma that has spread or cannot be removed. The treatment uses a patient's own immune cells (T cells) taken fro…

This study tests whether a supervised, at-home resistance training program using a tablet is safe and helpful for people with advanced pancreatic cancer or those recovering from surgery. About 25 participants will do guided exercises while on chemotherapy or after surgery. The go…